Published in Pulm Pharmacol Ther on June 15, 2012
Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med (2014) 2.28
Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. Am J Respir Crit Care Med (2015) 1.97
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther (2014) 0.90
ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation. Am J Respir Cell Mol Biol (2014) 0.84
Serum Lipoproteins Are Critical for Pulmonary Innate Defense against Staphylococcus aureus Quorum Sensing. J Immunol (2015) 0.81
Asthma and metabolic syndrome: Current knowledge and future perspectives. World J Clin Cases (2015) 0.80
Association of pulmonary function with adiposity and metabolic abnormalities in urban minority adolescents. Ann Am Thorac Soc (2014) 0.80
The Effect of Statins on Blood Gene Expression in COPD. PLoS One (2015) 0.79
Is serum cholesterol a risk factor for asthma? Lung India (2013) 0.78
Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease. Am J Respir Cell Mol Biol (2016) 0.76
Nutritional parameters affecting severity of pneumonia and length of hospital stay in patients with pneumococcal pneumonia: a retrospective cross-sectional study. BMC Pulm Med (2015) 0.76
Ozone-derived Oxysterols Affect Liver X Receptor (LXR) Signaling: A POTENTIAL ROLE FOR LIPID-PROTEIN ADDUCTS. J Biol Chem (2016) 0.75
Role for phospholipid acyl chains and cholesterol in pulmonary infections and inflammation. J Leukoc Biol (2016) 0.75
Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation. Respir Res (2017) 0.75
The weight of obesity on lung health. Pulm Pharmacol Ther (2013) 0.75
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Atherosclerosis. Nature (2000) 15.95
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol (2010) 5.90
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 4.96
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ (2006) 3.62
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One (2010) 3.15
Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med (2008) 3.10
Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 2.98
Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet (2009) 2.80
Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem (2005) 2.74
Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med (2007) 2.65
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18
Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med (2008) 2.14
Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol (2005) 2.13
Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA (2009) 2.10
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol (2006) 1.91
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol (2004) 1.88
Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med (2009) 1.86
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J (2007) 1.80
Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) (2009) 1.69
A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med (2010) 1.67
Statin use is associated with reduced mortality in COPD. Eur Respir J (2006) 1.66
Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med (2005) 1.62
Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy (2007) 1.61
Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax (2006) 1.60
A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med (2004) 1.60
Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. J Clin Invest (2007) 1.52
Potential therapeutic role for statins in respiratory disease. Thorax (2006) 1.49
ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol (2005) 1.46
Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun (2008) 1.39
Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med (2009) 1.38
Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf (2009) 1.37
Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation (2002) 1.37
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res (2007) 1.34
Loss of ABCG1 results in chronic pulmonary inflammation. J Immunol (2008) 1.32
Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol (2008) 1.32
Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest (2009) 1.29
Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med (2003) 1.28
A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol (2008) 1.28
Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax (2008) 1.26
Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol (2005) 1.21
Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol (2006) 1.21
D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation (2004) 1.20
Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract (2008) 1.20
The use of statins and lung function in current and former smokers. Chest (2007) 1.18
Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol (2010) 1.17
Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. Am J Respir Crit Care Med (2010) 1.16
Simvastatin treatment of pulmonary hypertension: an observational case series. Chest (2005) 1.15
D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res (2010) 1.14
5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol (2010) 1.13
Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med (2010) 1.13
Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J Biol Chem (2004) 1.13
Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol (2010) 1.13
Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res (2010) 1.12
Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J Immunol (2008) 1.11
Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax (2010) 1.09
Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J Lipid Res (1999) 1.08
Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest (2010) 1.06
Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med (2007) 1.04
Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.03
Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci (2004) 1.02
Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol (2009) 1.00
Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. BMC Pulm Med (2011) 1.00
SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J Lipid Res (2007) 1.00
Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J Inflamm Res (2011) 1.00
Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes. J Immunol (2010) 0.98
Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther (2011) 0.98
Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest (2004) 0.97
Apoetm1Unc mice have impaired alveologenesis, low lung function, and rapid loss of lung function. Am J Physiol Lung Cell Mol Physiol (2008) 0.97
Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J Biol Chem (2007) 0.97
Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research. Drug Metab Lett (2011) 0.97
Role of cholesterol in the biophysical dysfunction of surfactant in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2009) 0.95
ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am J Respir Crit Care Med (2010) 0.95
Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins. Am J Physiol (1997) 0.94
Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation (2008) 0.93
HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med (1999) 0.93
ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. J Immunol (2012) 0.93
Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine (2008) 0.92
Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci (2006) 0.92
Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J Biol Chem (2009) 0.90
Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts. Respir Res (2011) 0.89
Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol (2007) 0.89
Uptake, metabolism, and cytotoxicity of isomeric cholesterol-5,6-epoxides in rabbit aortic endothelial cells. J Lipid Res (1991) 0.89
Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. Am Rev Respir Dis (1986) 0.88
Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res (2010) 0.88
Dietary cholesterol enhances pulmonary eosinophilic inflammation in a murine model of asthma. Int Arch Allergy Immunol (2001) 0.87
Regulation of lung surfactant cholesterol metabolism by serum lipopoteins. Lipids (1980) 0.87
Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol (2010) 0.87
Inflammation, metabolic syndrome, and diet responsiveness. Circulation (2003) 0.85
The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol (2009) 0.85
Comparative study of the cytotoxicity and apoptosis-inducing potential of commonly occurring oxysterols. Cell Biol Toxicol (2001) 0.83
Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-κB expression. Mol Cell Biochem (2011) 0.78
Lipoproteins are major and primary mitogens and growth promoters for human arterial smooth muscle cells and lung fibroblasts in vitro. Arterioscler Thromb (1994) 0.78
The effect of elevated dietary cholesterol on pulmonary surfactant function in adolescent mice. Pediatr Pulmonol (2008) 0.77
Relation between objective measures of atopy and myocardial infarction in the United States. J Allergy Clin Immunol (2012) 1.98
Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol (2010) 1.94
Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res (2010) 1.82
Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun (2005) 1.79
Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol (2006) 1.62
Genetic polymorphisms and sepsis. Shock (2005) 1.50
Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling contributes to innate immune responses in the lung during Escherichia coli pneumonia. J Immunol (2007) 1.35
Mechanisms of neutrophil accumulation in the lungs against bacteria. Am J Respir Cell Mol Biol (2009) 1.28
The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet (2011) 1.27
Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-localize to uropod rafts in formylated Met-Leu-Phe-stimulated neutrophils. J Biol Chem (2004) 1.24
The structure of the dust mite allergen Der p 7 reveals similarities to innate immune proteins. J Allergy Clin Immunol (2010) 1.20
Obesity is associated with neutrophil dysfunction and attenuation of murine acute lung injury. Am J Respir Cell Mol Biol (2012) 1.13
Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J Immunol (2008) 1.11
p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res (2014) 1.09
Quantitative proteomics analysis of macrophage rafts reveals compartmentalized activation of the proteasome and of proteasome-mediated ERK activation in response to lipopolysaccharide. Mol Cell Proteomics (2008) 1.07
Crosstalk between reverse cholesterol transport and innate immunity. Trends Endocrinol Metab (2012) 1.04
CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action. Diabetes (2012) 1.04
Inhibition of c-Jun N-terminal kinase limits lipopolysaccharide-induced pulmonary neutrophil influx. Am J Respir Crit Care Med (2005) 1.04
Proteomic profiling of S-acylated macrophage proteins identifies a role for palmitoylation in mitochondrial targeting of phospholipid scramblase 3. Mol Cell Proteomics (2011) 1.02
Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab (2010) 1.01
Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes. J Immunol (2010) 0.98
ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am J Respir Crit Care Med (2010) 0.95
Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 0.94
ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. J Immunol (2012) 0.93
p53 Integrates host defense and cell fate during bacterial pneumonia. J Exp Med (2013) 0.89
Myeloid cell-specific ABCA1 deletion protects mice from bacterial infection. Circ Res (2012) 0.88
CD11b/CD18 (Mac-1) is a novel surface receptor for extracellular double-stranded RNA to mediate cellular inflammatory responses. J Immunol (2012) 0.88
A 70-year-old man with migratory pulmonary infiltrates. Chest (2006) 0.86
Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J Biol Chem (2012) 0.86
Effects of acute and chronic low density lipoprotein exposure on neutrophil function. Pulm Pharmacol Ther (2012) 0.84
Preferential invasion of mitotic cells by Salmonella reveals that cell surface cholesterol is maximal during metaphase. J Cell Sci (2013) 0.84
The IL-1 type 1 receptor is required for the development of LPS-induced airways disease. J Allergy Clin Immunol (2007) 0.83
ABCG1-mediated generation of extracellular cholesterol microdomains. J Lipid Res (2013) 0.83
Epitope mapping by proteolysis of antigen-antibody complexes. Methods Mol Biol (2009) 0.80
Apolipoprotein E-deficient mice are susceptible to the development of acute lung injury. Respiration (2014) 0.79
Statins enhance clearance of apoptotic cells through modulation of Rho-GTPases. Proc Am Thorac Soc (2006) 0.78
Greasing the way: the ABCs of HSPC efflux from the marrow. Cell Stem Cell (2012) 0.77
Simvastatin as a potential therapeutic for acute respiratory distress syndrome. Am J Respir Crit Care Med (2009) 0.76
Epitope mapping by differential chemical modification of antigens. Methods Mol Biol (2009) 0.75
Laboratory predictors of relative adrenal insufficiency in septic shock. Crit Care Med (2003) 0.75
A new inflammatory role for p53 in human macrophages. Cell Cycle (2014) 0.75
Reply: To PMID 22921873. J Allergy Clin Immunol (2013) 0.75
An Official American Thoracic Society Workshop Report: Obesity and Metabolism. An Emerging Frontier in Lung Health and Disease. Ann Am Thorac Soc (2017) 0.75
New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc (2017) 0.75